about
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa as haemostatic therapy in advanced liver diseaseThe Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.Transfusion medicine service policies for recombinant factor VIIa administration.Recombinant activated factor VII in patients at high risk of bleeding.Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin.Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.The first case of postpartum acquired hemophilia A in Korea.Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settingsProlonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.Aortic valve replacement in a Jehovah's Witness: a case of multi-disciplinary clinical management for bloodless surgery.Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplantRecombinant factor VIIa in the treatment of non-hemophiliac bleeding.Acquired coagulation inhibitor-associated bleeding disorders: an update.Management of bleeding emergencies: when to use recombinant activated factor VII.A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.Acquired hemophilia A.Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief reviewSafety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhageTreatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery.The use of recombinant activated factor VII in platelet-associated bleeding.The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.Novel approaches to the treatment of intracerebral haemorrhage.Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: experience from a university hospital in Taiwan.Update and new developments in the management of the exsanguinating patient.Timely 'off-label' use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature.NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa.Use of recombinant activated factor VII for intractable bleeding in patients without hemophilia: A developing country tertiary care center's experience.
P2860
Q24201292-E1174D05-C6AB-42DF-A30C-38007A399512Q24236583-E8B77189-E1B1-450F-A0F6-D99F50F34F49Q24245204-B185FD85-0CD9-41D4-84EA-01005C2DB91EQ26822857-2FC1B03E-1AB7-40F0-B4C7-3307A2FF695DQ30833127-DA2957D8-1F2B-452A-9E0D-2DF9010248A4Q33362187-19BC7962-C20A-41F6-8388-003BA8E610FDQ33365354-E11258DE-CA51-47CC-88E8-FB9B7C136B63Q33370641-3C1135D1-97DC-48F3-B8A2-F8F294121524Q33394197-CF7FE538-5C3E-4701-B88F-C1AA3B2FAF2BQ35211987-542A4B5E-C173-4880-9669-7384DF60EA56Q35578941-3CACA14E-9CEA-4D22-B4F5-D0EF7C12170CQ35666533-A2B6AE19-78FC-4D03-B8B6-35D9298DF1E6Q35771690-5814B9BE-4422-460B-AF28-DA2BED936DA9Q35792538-B4545004-07AD-48D4-A210-7476820AC9E7Q35839531-88D0C631-8CEE-4F4C-A547-F8391D421E30Q35924900-826F3D55-325A-4B2B-916B-F35B8BDE4387Q36077574-7D3625A0-BA35-4D74-AB50-0574730F8F85Q36328387-34BB324C-3D7C-4781-A1E8-0FD309E3D2E9Q36349585-C176808C-5474-4488-B36B-EDDC938C6C45Q36462093-2FAEBDE4-89ED-4C12-8CC7-A02138CCB9C4Q36497382-83961854-51BF-4F2F-9C4F-7804BC5551D1Q36570888-14912986-54CD-4B3E-B9B6-C355F67BB8C3Q36603284-04675473-D1C9-401F-8208-53D9757BE86AQ36646985-6E765443-29CA-4F94-A120-6BAE1AD2615EQ36912173-9C3F5DBB-CBF7-4587-942B-698DA210D5CEQ36945941-7D978E1C-2E50-45A2-AF8C-D1C6FBB049F8Q37095548-3AB18CD7-55BC-495C-82BC-BCFFF11FC989Q37183517-F0A97984-476B-4466-B9BC-0319C7FD2B70Q37416007-BA3658AE-DCB4-4885-B563-32645C999E50Q37807082-2BDAE2B5-2473-43FD-82F8-FB6B038F7EEFQ37898741-F2BAC9C5-B4BF-4ADA-B236-52D1DA183E7FQ37900080-56ED31B1-3B20-4BD7-BFD4-797D60A1D1B1Q38005104-7C2234F7-F1B1-4EBA-8977-282A9481AA31Q38267207-1510D252-5995-49A2-9BD2-F8D0923ECBDCQ42112270-6C96643F-9B48-4A71-8246-0601F410002BQ44963707-89EBA4FE-8E8E-4ADF-8C1C-DE822A04A536Q45863907-A1FFF878-C327-4040-A02D-6A6408188550Q45865634-C990CD55-2B6A-4639-AD8D-4B019FE74730Q45872689-4C93538B-70EA-4716-9F70-5FA978B6DCFDQ45887641-BF6CE005-E318-4A07-B16B-4EC0DF3C7EFC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Potential role for rFVIIa in transfusion medicine.
@ast
Potential role for rFVIIa in transfusion medicine.
@en
Potential role for rFVIIa in transfusion medicine.
@nl
type
label
Potential role for rFVIIa in transfusion medicine.
@ast
Potential role for rFVIIa in transfusion medicine.
@en
Potential role for rFVIIa in transfusion medicine.
@nl
prefLabel
Potential role for rFVIIa in transfusion medicine.
@ast
Potential role for rFVIIa in transfusion medicine.
@en
Potential role for rFVIIa in transfusion medicine.
@nl
P2860
P1433
P1476
Potential role for rFVIIa in transfusion medicine.
@en
P2093
Elisabeth Erhardtsen
Ulla Hedner
P2860
P304
P356
10.1046/J.1537-2995.2002.00017.X
P577
2002-01-01T00:00:00Z